On July 1, 2021 Orion Biotech Opportunities Corp. (Nasdaq: ORIAU) (the "Company" or "us") reported that, commencing July 2, 2021, holders of the units sold in the Company’s initial public offering of 20,000,000 units, completed on May 17, 2021, may elect to separately trade the Class A ordinary shares and warrants included in the units (Press release, Orion Biotechnology, JUL 1, 2021, View Source [SID1234584557]). Those units that are not separated at the election of the holder will continue to trade on the Nasdaq Stock Market LLC ("Nasdaq") under the symbol "ORIAU," and the Class A ordinary shares and warrants that are separated will trade on the Nasdaq under the symbols "ORIA" and "ORIAW," respectively. Holders of the units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A ordinary shares and warrants.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The units were initially offered by the Company in an underwritten offering. Cantor Fitzgerald & Co. acted as the book running manager for the offering. A registration statement relating to the units and the underlying securities was declared effective by the Securities and Exchange Commission (the "SEC") on May 12, 2021.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.